- Trials with a EudraCT protocol (508)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
508 result(s) found for: Cognitive therapy.
Displaying page 1 of 26.
EudraCT Number: 2016-001248-20 | Sponsor Protocol Number: COG-PRO | Start Date*: 2016-07-20 |
Sponsor Name:Centre François Baclesse | ||
Full Title: Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer | ||
Medical condition: Metastatic prostate cancer | ||
Disease: | ||
Population Age: Elderly | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005383-22 | Sponsor Protocol Number: Kognition | Start Date*: 2022-07-27 |
Sponsor Name:Universitätsmedizin Göttingen | ||
Full Title: Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) | ||
Medical condition: Iron deficiency in patients with chronic heart failure and mild cognitive impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000342-19 | Sponsor Protocol Number: IIT-2017/02 | Start Date*: 2018-10-18 |
Sponsor Name:Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät | ||
Full Title: Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzhei... | ||
Medical condition: Included are patients with the presence of a moderate or pronounced zinc deficienc and the diagnosis of a mild cognitive disorder, which may be due to an additional investigation (amyloid PET and /... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017581-22 | Sponsor Protocol Number: 20091003 | Start Date*: 2011-01-04 |
Sponsor Name:Department of Psychiatry and Psychotherapy, Charity University Medicine | ||
Full Title: Cognitive impairment in bipolar disorder treated with aripiprazole | ||
Medical condition: Bipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004393-41 | Sponsor Protocol Number: 2004 | Start Date*: 2015-05-13 |
Sponsor Name:CUB Hospital Erasme | ||
Full Title: A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depre... | ||
Medical condition: The subjects enrolled in the study will be major patients with major depressive disorder diagnosed according to DSM-IV, receiving electroconvulsive therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001846-42 | Sponsor Protocol Number: CAQW051A2104 | Start Date*: 2007-10-05 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent w... | ||||||||||||||||||
Medical condition: Mild Alzheimer’s disease (AD) and amnestic mild cognitive impairment (amnestic MCI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005859-18 | Sponsor Protocol Number: SC05-03 | Start Date*: 2006-06-13 | |||||||||||
Sponsor Name:FONDAZIONE SANTA LUCIA | |||||||||||||
Full Title: EFFECT OF MEMANTINE TREATMENT ON BRAIN FUNCTION AND MORPHOLOGICAL STRUCTURE IN PATIENTS WITH MODERATE TO SEVERE PATIENTS WITH ALZHEIMER S DISEASE A STRUCTURAL MR AND FMRI STUDY | |||||||||||||
Medical condition: Moderate to severe Alzheimer s disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003209-92 | Sponsor Protocol Number: EVP-6124-016 | Start Date*: 2013-10-22 | ||||||||||||||||
Sponsor Name:Forum Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003208-10 | Sponsor Protocol Number: EVP-6124-015 | Start Date*: 2013-06-28 | ||||||||||||||||
Sponsor Name:Forum Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000506-11 | Sponsor Protocol Number: Lx-Gf01 | Start Date*: 2017-06-06 |
Sponsor Name:Limoxifen BV | ||
Full Title: Proof-of-concept study on treating cognitive side-effects of Tamoxifen with guanfacine in postmenopausal women with E2/Pg receptor-positive breast cancer. | ||
Medical condition: Memory loss, attention deficit | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002171-11 | Sponsor Protocol Number: 010622 | Start Date*: 2024-07-02 |
Sponsor Name:Medical University of Łódź | ||
Full Title: Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic functional connectivity, cognitive functions, quality of ... | ||
Medical condition: dementia and mild cognitice impairment due to Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003228-19 | Sponsor Protocol Number: EVP-6124-017 | Start Date*: 2014-02-26 | ||||||||||||||||
Sponsor Name:EnVivo Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an ... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed) GB (Completed) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000740-10 | Sponsor Protocol Number: 901809 | Start Date*: 2020-03-05 | ||||||||||||||||||||||||||
Sponsor Name:NUI As | ||||||||||||||||||||||||||||
Full Title: Hyperbaric oxygen therapy after cerebral infarction | ||||||||||||||||||||||||||||
Medical condition: Chronic physical and/or cognitive imparement after cerebral infarction. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NO (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003176-40 | Sponsor Protocol Number: CHEMOCIM | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:AZIENDA USL TOSCANA NORD OVEST | |||||||||||||
Full Title: Randomised, clinical trial, controlled, open-label, multicenter, non-profit study to evaluate the superiority of a complementary treatment with additional Homeopathic Medicines and Acupuncture / Au... | |||||||||||||
Medical condition: Primary diagnosis of breast cancer (stage: I-III A) treated with adjuvant chemotherapy and / or endocrine therapy after surgical treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002713-35 | Sponsor Protocol Number: AXCT01-01-03-2013 | Start Date*: 2014-07-29 | |||||||||||
Sponsor Name:MediPsych SA | |||||||||||||
Full Title: Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001839-23 | Sponsor Protocol Number: 14137A | Start Date*: 2012-05-14 |
Sponsor Name:H. Lundbeck A/S | ||
Full Title: Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted fro... | ||
Medical condition: Cognitive dysfunction Major depressive disorder (MDD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003542-68 | Sponsor Protocol Number: | Start Date*: 2016-01-27 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial | |||||||||||||
Medical condition: DSM panic disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002213-19 | Sponsor Protocol Number: ELICE-BD-O1 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:University of British Columbia | |||||||||||||
Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa... | |||||||||||||
Medical condition: Euthymic Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000258-64 | Sponsor Protocol Number: D1449L00004 | Start Date*: 2005-04-08 |
Sponsor Name:AstraZeneca AB | ||
Full Title: SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Co... | ||
Medical condition: Schizophrenia is a chronic psychiatric disorder that often begins during adolescence or early adulthood. A major problem for patients with schizophrenia is a cognitive deficit compared to a control... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002326-36 | Sponsor Protocol Number: 2016-858 | Start Date*: 2016-11-09 | ||||||||||||||||
Sponsor Name:Region Hovedstadens psykiatriske hospital | ||||||||||||||||||
Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) | ||||||||||||||||||
Medical condition: Unipolar/bipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
